Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine effect on ropivacaine EC50 for adductor canal + sciatic nerve block in TKA
ChiCTR2300075759Phase 4Not yet recruiting
- Sponsor
- Hai'an Hospital of Traditional Chinese Medicine
- Start
- Sep 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of ropivacaine and dexmedetomidine in osteoarthritis (OA) and knee osteoarthritis (OA) (2 arms), sponsored by Hai'an Hospital of Traditional Chinese Medicine. Primary endpoints: Half effective concentration (EC50) of ropivacaine, 95% effective concentration (EC95) of ropivacaine and 2 more. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
ropivacainedexmedetomidine
03
Conditions
osteoarthritis (OA)knee osteoarthritis (OA)
Beyond the preview
Go deeper on ChiCTR2300075759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075759.